BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885-1892. [PMID: 9607928 DOI: 10.1084/jem.187.11.1885] [Cited by in Crossref: 406] [Cited by in F6Publishing: 380] [Article Influence: 16.9] [Reference Citation Analysis]
Number Citing Articles
1 Quach H, Kalff A, Spencer A. Lenalidomide in multiple myeloma: Current status and future potential. Am J Hematol 2012;87:1089-95. [DOI: 10.1002/ajh.23234] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
2 Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene 2013;32:4191-202. [DOI: 10.1038/onc.2012.599] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
3 Eleutherakis-papaiakovou V, Karali M, Kokkonouzis I, Tiliakos I, Dimopoulos M. Bone Marrow Angiogenesis and Progression in Multiple Myeloma: Clinical Significance and Therapeutic Approach. Leukemia & Lymphoma 2009;44:937-48. [DOI: 10.1080/1042819031000067639] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
4 Jansen van Rensburg CE, Naude PJ. Potassium Humate Inhibits Complement Activation and the Production of Inflammatory Cytokines In Vitro. Inflammation 2009;32:270-6. [DOI: 10.1007/s10753-009-9130-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
5 Lehman TJ. Thalidomide for rheumatic disease: the best of both worlds? Nat Clin Pract Rheumatol 2007;3:308-9. [PMID: 17538563 DOI: 10.1038/ncprheum0504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
6 Oliver SJ, Kikuchi T, Krueger JG, Kaplan G. Thalidomide Induces Granuloma Differentiation in Sarcoid Skin Lesions Associated with Disease Improvement. Clinical Immunology 2002;102:225-36. [DOI: 10.1006/clim.2001.5173] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 2.5] [Reference Citation Analysis]
7 Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer. 2005;103:119-125. [PMID: 15565573 DOI: 10.1002/cncr.20732] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
8 Martino M, Console G, Callea V, Stelitano C, Massara E, Irrera G, Messina G, Morabito F, Iacopino P. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. Eur J Haematol 2007;78:35-40. [DOI: 10.1111/j.1600-0609.2006.00774.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
9 Bullok KF, Sippel C, Schmidt-wolf IG. Increased effect of IMiDs by addition of cytokine-induced killer cells in multiple myeloma: Combination of IMiDs and CIK cells in multiple myeloma. Hematol Oncol 2016;34:208-16. [DOI: 10.1002/hon.2200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M, Bicciato S, Nico B, Ribatti D, Dammacco F, Corradini P. Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma. JCO 2005;23:5334-46. [DOI: 10.1200/jco.2005.03.723] [Cited by in Crossref: 86] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
11 Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 2005;93:613-9. [PMID: 16222306 DOI: 10.1038/sj.bjc.6602774] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
12 Bousvaros A, Mueller B. Thalidomide in gastrointestinal disorders. Drugs. 2001;61:777-787. [PMID: 11398909 DOI: 10.2165/00003495-200161060-00006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
13 Kastritis E, Charidimou A, Varkaris A, Dimopoulos MA. Targeted therapies in multiple myeloma. Target Oncol 2009;4:23-36. [PMID: 19343299 DOI: 10.1007/s11523-008-0102-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
14 LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90. [PMID: 14512311 DOI: 10.1182/blood-2003-02-0361] [Cited by in Crossref: 206] [Cited by in F6Publishing: 195] [Article Influence: 10.8] [Reference Citation Analysis]
15 Jacobson JM. Thalidomide: a remarkable comeback. Expert Opinion on Pharmacotherapy 2005;1:849-63. [DOI: 10.1517/14656566.1.4.849] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
16 Meierhofer C, Dunzendorfer S, Wiedermann CJ. Theoretical basis for the activity of thalidomide. BioDrugs. 2001;15:681-703. [PMID: 11604049 DOI: 10.2165/00063030-200115100-00005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
17 McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012;2012:513702. [PMID: 22888354 DOI: 10.1155/2012/513702] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
18 Galustian C, Labarthe M, Bartlett JB, Dalgleish AG. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opinion on Biological Therapy 2005;4:1963-70. [DOI: 10.1517/14712598.4.12.1963] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
19 Yee KW, O'Brien SM. Emerging drugs for chronic lymphocytic leukaemia. Expert Opin Emerg Drugs 2006;11:167-89. [PMID: 16503834 DOI: 10.1517/14728214.11.1.167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Brightman L, Demierre M. Thalidomide in mycosis fungoides. Journal of the American Academy of Dermatology 2005;52:1100-1. [DOI: 10.1016/j.jaad.2005.01.104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618-21. [PMID: 16569772 DOI: 10.1182/blood-2005-10-4184] [Cited by in Crossref: 202] [Cited by in F6Publishing: 188] [Article Influence: 12.6] [Reference Citation Analysis]
22 Gao S, Wang S, Song Y. Novel immunomodulatory drugs and neo-substrates. Biomark Res 2020;8:2. [PMID: 31938543 DOI: 10.1186/s40364-020-0182-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
23 Ge Y, Montano I, Rustici G, Freebern WJ, Haggerty CM, Cui W, Ponciano-Jackson D, Chandramouli GV, Gardner ER, Figg WD, Abu-Asab M, Tsokos M, Jackson SH, Gardner K. Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood 2006;108:4126-35. [PMID: 16940421 DOI: 10.1182/blood-2006-04-017046] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
24 Damaj G, Lefrère F, Delarue R, Varet B, Furman R, Hermine O. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 2003;17:1914-5. [DOI: 10.1038/sj.leu.2403058] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
25 Child JA, Russell N, Sonneveld P, Schey S. Future Directions in Multiple Myeloma Treatment. Acta Haematol 2005;114:8-13. [DOI: 10.1159/000087038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
26 Balza E, Carnemolla B, Orecchia P, Rubartelli A, Poggi A, Mortara L. Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency. Curr Med Chem 2020;27:4233-48. [PMID: 30182839 DOI: 10.2174/0929867325666180904121118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Verbon A, Juffermans NP, Speelman P, van Deventer SJ, ten Berge IJ, Guchelaar HJ, van der Poll T. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother. 2000;44:2286-2290. [PMID: 10952569 DOI: 10.1128/aac.44.9.2286-2290.2000] [Cited by in Crossref: 40] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
28 Du L, Zhang L, Li L, Li X, Yan J, Wang X, Fu X, Sun Z, Zhang X, Li Z, Wu J, Yu H, Chang Y, Zhou Z, Nan F, Wu X, Tian L, Zhang M. Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases. Onco Targets Ther 2020;13:7189-97. [PMID: 32801749 DOI: 10.2147/OTT.S262039] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Cavenagh JD, Oakervee H; on behalf of the UK Myeloma Forum and The BCSH Haematology/Oncology Task Forces. Thalidomide in multiple myeloma: current status and future prospects: Guideline. British Journal of Haematology 2003;120:18-26. [DOI: 10.1046/j.1365-2141.2003.03902.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 2.6] [Reference Citation Analysis]
30 Stansfield LC, Gonsalves WI, Buadi FK. The use of novel agents in multiple myeloma patients with hepatic impairment. Future Oncol 2015;11:501-10. [PMID: 25675129 DOI: 10.2217/fon.14.270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
31 Martinez-Høyer S, Karsan A. Mechanisms of lenalidomide sensitivity and resistance. Exp Hematol 2020;91:22-31. [PMID: 32976949 DOI: 10.1016/j.exphem.2020.09.196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Kumar R, Kolloli A, Singh P, Vinnard C, Kaplan G, Subbian S. Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model. Front Cell Infect Microbiol 2019;9:450. [PMID: 32010638 DOI: 10.3389/fcimb.2019.00450] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Aue G, Sun C, Liu D, Park JH, Pittaluga S, Tian X, Lee E, Soto S, Valdez J, Maric I, Stetler-Stevenson M, Yuan C, Nakamura Y, Muranski P, Wiestner A. Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. J Immunol 2018;201:1967-74. [PMID: 30104242 DOI: 10.4049/jimmunol.1800570] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
34 Rajkumar S, Dispenzieri A, Fonseca R, Lacy M, Geyer S, Lust J, Kyle R, Greipp P, Gertz M, Witzig T. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001;15:1274-6. [DOI: 10.1038/sj.leu.2402183] [Cited by in Crossref: 120] [Cited by in F6Publishing: 98] [Article Influence: 5.7] [Reference Citation Analysis]
35 Biagi J, Mileshkin L, Grigg A, Westerman D, Prince H. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001;28:1145-50. [DOI: 10.1038/sj.bmt.1703292] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
36 Dowlati A, Subbiah S, Cooney M, Rutherford K, Mekhail T, Fu P, Chapman R, Ness A, Cortas T, Saltzman J, Levitan N, Warren G. Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer 2007;56:377-81. [DOI: 10.1016/j.lungcan.2007.01.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
37 Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, Chott A, Drach J. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104:2269-71. [DOI: 10.1182/blood-2004-03-1091] [Cited by in Crossref: 125] [Cited by in F6Publishing: 113] [Article Influence: 6.9] [Reference Citation Analysis]
38 Amato RJ, Malya R, Rawat A. Phase II Study of Combination Thalidomide/Interleukin-2 Therapy Plus Granulocyte Macrophage-Colony Stimulating Factor in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology 2008;31:237-43. [DOI: 10.1097/coc.0b013e31815e4505] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
39 Badamtseren B, Odkhuu E, Koide N, Haque A, Naiki Y, Hashimoto S, Komatsu T, Yoshida T, Yokochi T. Thalidomide inhibits interferon-γ-mediated nitric oxide production in mouse vascular endothelial cells. Cellular Immunology 2011;270:19-24. [DOI: 10.1016/j.cellimm.2011.03.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
40 Shannon EJ, Sandoval FG. Thalidomide can costimulate or suppress CD4+ cells' ability to incorporate [H3]-thymidine—dependence on the primary stimulant. International Immunopharmacology 2002;2:1143-53. [DOI: 10.1016/s1567-5769(02)00066-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Eisen T. Thalidomide in solid malignancies. J Clin Oncol 2002;20:2607-9. [PMID: 12039920 DOI: 10.1200/JCO.2002.20.11.2607] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Stirling DI. Pharmacology of thalidomide. Seminars in Hematology 2000;37:5-14. [DOI: 10.1016/s0037-1963(00)90077-5] [Cited by in Crossref: 33] [Article Influence: 1.5] [Reference Citation Analysis]
43 Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol 2013;41:387-97.e1. [PMID: 23178378 DOI: 10.1016/j.exphem.2012.11.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
44 Ng S, Brown M, Figg W. Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomedicine & Pharmacotherapy 2002;56:194-9. [DOI: 10.1016/s0753-3322(02)00177-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
45 Tarhini AA, Agarwala SS. Novel agents in development for the treatment of melanoma. Expert Opinion on Investigational Drugs 2005;14:885-92. [DOI: 10.1517/13543784.14.7.885] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
46 Chave T, Mortimer N, Sladden M, Hall A, Hutchinson P. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005;153:241-53. [DOI: 10.1111/j.1365-2133.2005.06721.x] [Cited by in Crossref: 151] [Cited by in F6Publishing: 121] [Article Influence: 8.9] [Reference Citation Analysis]
47 Cem Ar M, Soysal T, Hatemi G, Salihoglu A, Yazici H, Ulku B. Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. Ann Hematol 2005;84:609-13. [DOI: 10.1007/s00277-005-1053-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kröger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H, Renges H, Fehse B, Zabelina T, Nagler A, Zander AR. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004;104:3361-3. [DOI: 10.1182/blood-2004-05-2031] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 4.9] [Reference Citation Analysis]
49 Mentlik James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013;4:481. [PMID: 24391651 DOI: 10.3389/fimmu.2013.00481] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
50 Oliver SJ. Nonpulmonary manifestations of sarcoidosis. Curr Rheumatol Rep 2002;4:170-8. [PMID: 11890883 DOI: 10.1007/s11926-002-0013-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
51 Haslett PA, Klausner JD, Makonkawkeyoon S, Moreira A, Metatratip P, Boyle B, Kunachiwa W, Maneekarn N, Vongchan P, Corral LG, Elbeik T, Shen Z, Kaplan G. Thalidomide Stimulates T Cell Responses and Interleukin 12 Production in HIV-Infected Patients. AIDS Research and Human Retroviruses 1999;15:1169-79. [DOI: 10.1089/088922299310269] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 2.7] [Reference Citation Analysis]
52 Meyers DE, Thakur S, Thirukkumaran CM, Morris DG. Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. Blood Cancer J 2017;7:640. [PMID: 29208938 DOI: 10.1038/s41408-017-0020-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
53 Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV. Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings 2003;78:34-9. [DOI: 10.4065/78.1.34] [Cited by in Crossref: 103] [Cited by in F6Publishing: 86] [Article Influence: 5.4] [Reference Citation Analysis]
54 Cives M, Simone V, Brunetti O, Longo V, Silvestris F. Novel lenalidomide-based combinations for treatment of multiple myeloma. Critical Reviews in Oncology/Hematology 2013;85:9-20. [DOI: 10.1016/j.critrevonc.2012.06.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
55 Neparidze N, Dhodapkar MV. Harnessing CD1d-restricted T cells toward antitumor immunity in humans. Ann N Y Acad Sci 2009;1174:61-7. [PMID: 19769737 DOI: 10.1111/j.1749-6632.2009.04931.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
56 Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Thalidomide in the Treatment of Relapsed Multiple Myeloma. Mayo Clinic Proceedings 2000;75:897-901. [DOI: 10.4065/75.9.897] [Cited by in Crossref: 125] [Cited by in F6Publishing: 103] [Article Influence: 5.7] [Reference Citation Analysis]
57 Payvandi F, Wu L, Naziruddin SD, Haley M, Parton A, Schafer PH, Chen RS, Muller GW, Hughes CC, Stirling DI. Immunomodulatory Drugs (IMiDs) Increase the Production of IL-2 from Stimulated T Cells by Increasing PKC-θ Activation and Enhancing the DNA-Binding Activity of AP-1 but Not NF-κB, OCT-1, or NF-AT. Journal of Interferon & Cytokine Research 2005;25:604-16. [DOI: 10.1089/jir.2005.25.604] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
58 Shannon E, Noveck R, Sandoval F, Kamath B. Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide. Immunopharmacol Immunotoxicol 2008;30:447-57. [PMID: 18668392 DOI: 10.1080/08923970802135161] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
59 Zidi I, Mestiri S, Bartegi A, Amor NB. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27:185-198. [PMID: 19277912 DOI: 10.1007/s12032-009-9190-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
60 Weng Q, Wang J, Wang J, Wang J, Sattar F, Zhang Z, Zheng J, Xu Z, Zhao M, Liu X, Yang L, Hao G, Fang L, Lu QR, Yang B, He Q. Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization. Cell Death Dis 2018;9:251. [PMID: 29445144 DOI: 10.1038/s41419-018-0290-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
61 Muscal JA, Sun Y, Nuchtern JG, Dauser RC, McGuffey LH, Gibson BW, Berg SL. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol 2012;69:943-7. [PMID: 22109830 DOI: 10.1007/s00280-011-1781-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
62 Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002;16:1-6. [PMID: 11840256 DOI: 10.1038/sj.leu.2402330] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 5.5] [Reference Citation Analysis]
63 Schoeman JF, Springer P, Ravenscroft A, Donald PR, Bekker L, van Rensburg AJ, Hanekom WA, Haslett PAJ, Kaplan G. Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role. J Child Neurol 2000;15:497-503. [DOI: 10.1177/088307380001500801] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
64 Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment: . Current Opinion in Oncology 2000;12:564-73. [DOI: 10.1097/00001622-200011000-00009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
65 Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519-27. [PMID: 11494147 DOI: 10.1038/sj.onc.1204623] [Cited by in Crossref: 277] [Cited by in F6Publishing: 240] [Article Influence: 13.2] [Reference Citation Analysis]
66 Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B, Wheeler ML, Bezman N, Wang F, Strop P, Leif Bergsagel P, Chesi M. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov 2021;2:354-69. [PMID: 34258584 DOI: 10.1158/2643-3230.bcd-21-0038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Díaz-Tejedor A, Lorenzo-Mohamed M, Puig N, García-Sanz R, Mateos MV, Garayoa M, Paíno T. Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers (Basel) 2021;13:1353. [PMID: 33802806 DOI: 10.3390/cancers13061353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
68 Schey S, Cavenagh J, Johnson R, Child J, Oakervee H, Jones R. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leukemia Research 2003;27:909-14. [DOI: 10.1016/s0145-2126(03)00027-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
69 Ji D, Li Q, Cao J, Guo Y, Lv F, Liu X, Wang B, Wang L, Luo Z, Chang J, Wu X, Hong X. Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. Oncotarget 2016;7:33331-9. [PMID: 27129176 DOI: 10.18632/oncotarget.8973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
70 Leite MR, Santos SS, Lyra AC, Mota J, Santana GO. Thalidomide induces mucosal healing in Crohn's disease: Case report. World J Gastroenterol 2011; 17(45): 5028-5031 [PMID: 22174554 DOI: 10.3748/wjg.v17.i45.5028] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
71 Amato RJ, Morgan M, Rawat A. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer 2006;106:1498-506. [DOI: 10.1002/cncr.21737] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
72 Hus I, Dmoszynska A, Manko J, Hus M, Jawniak D, Soroka-Wojtaszko M, Hellmann A, Ciepluch H, Skotnicki A, Wolska-Smolen T, Sulek K, Robak T, Konopka L, Kloczko J. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Br J Cancer 2004;91:1873-9. [PMID: 15520820 DOI: 10.1038/sj.bjc.6602225] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
73 Dimopoulos MA, Kastritis E, Rajkumar SV. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 2008;22:1343-53. [PMID: 18509355 DOI: 10.1038/leu.2008.123] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
74 Vulfovich M, Saba N. Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs 2005;13:577-607. [DOI: 10.1517/13543784.13.6.577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
75 van Deventer SJ. Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 2002;50 Suppl 3:III47-53. [PMID: 11953333 DOI: 10.1136/gut.50.suppl_3.iii47] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
76 Nakata J, Isohashi K, Oka Y, Nakajima H, Morimoto S, Fujiki F, Oji Y, Tsuboi A, Kumanogoh A, Hashimoto N, Hatazawa J, Sugiyama H. Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics (Basel) 2021;11:1041. [PMID: 34198874 DOI: 10.3390/diagnostics11061041] [Reference Citation Analysis]
77 Mya DH, Han ST, Linn YC, Hwang WY, Goh YT, Tan DC. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol. 2012;23:421-426. [PMID: 21551005 DOI: 10.1093/annonc/mdr142] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
78 Kastritis E, Dimopoulos MA. Thalidomide in the treatment of multiple myeloma. Best Pract Res Clin Haematol 2007;20:681-99. [PMID: 18070713 DOI: 10.1016/j.beha.2007.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
79 Gockel HR, Lügering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T, Lügering N. Thalidomide Induces Apoptosis in Human Monocytes by Using a Cytochrome c -Dependent Pathway. J Immunol 2004;172:5103-9. [DOI: 10.4049/jimmunol.172.8.5103] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
80 Santos ES, Kharfan-Dabaja MA. New horizons in multiple myeloma therapy. Expert Rev Anticancer Ther 2006;6:1483-501. [PMID: 17069532 DOI: 10.1586/14737140.6.10.1483] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Hwu W, Ayala AE, Hernandez IM. Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma. Oncol Rev 2008;2:183-93. [DOI: 10.1007/s12156-008-0073-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Morgan GJ, Davies FE. Role of thalidomide in the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol 2013;88 Suppl 1:S14-22. [PMID: 23827438 DOI: 10.1016/j.critrevonc.2013.05.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
83 Choe JY, Jung HJ, Park KY, Kum YS, Song GG, Hyun DS, Park SH, Kim SK. Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm Res 2010;59:177-88. [PMID: 19757088 DOI: 10.1007/s00011-009-0084-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
84 Downs LS Jr, Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, Boente MP, Nahhas WA, Abu-Ghazaleh SZ, Chen MD, Carson LF. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008;112:331-9. [PMID: 18058810 DOI: 10.1002/cncr.23164] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
85 Lasco TM, Cassone L, Kamohara H, Yoshimura T, Mcmurray DN. Evaluating the role of tumor necrosis factor-alpha in experimental pulmonary tuberculosis in the guinea pig. Tuberculosis 2005;85:245-58. [DOI: 10.1016/j.tube.2005.01.001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
86 Kasamatsu T, Kimoto M, Takahashi N, Minato Y, Gotoh N, Takizawa M, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Saitoh T, Murakami H. IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma. Hematological Oncology 2018;36:196-201. [DOI: 10.1002/hon.2469] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
87 Brown RD, Spencer A, Joy Ho P, Kennedy N, Kabani K, Yang S, Sze DM, Aklilu E, Gibson J, Joshua DE. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leukemia & Lymphoma 2009;50:1860-4. [DOI: 10.3109/10428190903216804] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
88 van Toorn R, Zaharie SD, Seddon JA, van der Kuip M, Marceline van Furth A, Schoeman JF, Solomons RS. The use of thalidomide to treat children with tuberculosis meningitis: A review. Tuberculosis (Edinb) 2021;130:102125. [PMID: 34500217 DOI: 10.1016/j.tube.2021.102125] [Reference Citation Analysis]
89 Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002;100:4162-8. [DOI: 10.1182/blood-2002-03-0939] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
90 Nakano T, Araki K, Nakatani H, Kobayashi M, Sugimoto T, Furuya Y, Matsuoka T, Jin T, Hanazaki K. Effects of geldanamycin and thalidomide on the Th1/Th2 cytokine balance in mice subjected to operative trauma. Surgery 2007;141:490-500. [DOI: 10.1016/j.surg.2006.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
91 Herth I, Witzens-Harig M, Beckhove P, Hose D, Meissner T, Neuber B, Engelhardt M, Haas J, Neben K, Ho AD, Klein B, Goldschmidt H, Hundemer M. Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma. Exp Hematol 2013;41:231-40. [PMID: 23142220 DOI: 10.1016/j.exphem.2012.10.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
92 Richardson P, Hideshima T, Anderson K. Thalidomide in multiple myeloma. Biomed Pharmacother 2002;56:115-28. [PMID: 12046682 DOI: 10.1016/s0753-3322(02)00168-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
93 Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma: Thalidomide in Refractory or Relapsing Myeloma. British Journal of Haematology 2000;109:89-96. [DOI: 10.1046/j.1365-2141.2000.01983.x] [Cited by in Crossref: 170] [Cited by in F6Publishing: 145] [Article Influence: 12.1] [Reference Citation Analysis]
94 Manning D. 71 IMMUNOMODULATORY AGENTS FOR NEUROPATHIC PAIN SYNDROMES: FROM ANIMALS TO CRPS AND BEYOND. European Journal of Pain 2006;10:S20b-S21. [DOI: 10.1016/s1090-3801(06)60074-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
95 Renault CA, Ernst JD. Mycobacterium leprae. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 3165-76. [DOI: 10.1016/b978-0-443-06839-3.00251-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
96 Balleari E, Ghio R, Falcone A, Musto P. Possible Multiple Myeloma Dedifferentiation Following Thalidomide Therapy: A Report of Four Cases. Leukemia & Lymphoma 2009;45:735-8. [DOI: 10.1080/10428190310001617231] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
97 Idler I, Bhattacharya N, Döhner H, Stilgenbauer S, Mertens D. Immune modulatory agents in hematopoietic malignancies. Cancer Treatment Reviews 2011;37:S2-7. [DOI: 10.1016/j.ctrv.2011.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
98 Rowland TL, Mchugh SM, Deighton J, Ewan PW, Dearman RJ, Kimber I. Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor α by thalidomide: comparisons with dexamethasone. Immunology Letters 1999;68:325-32. [DOI: 10.1016/s0165-2478(99)00055-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
99 Mccarthy DA, Macey MG, Streetly M, Schey SA, Brown KA. The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. International Immunopharmacology 2006;6:1194-203. [DOI: 10.1016/j.intimp.2006.03.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
100 Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001;92:2364-73. [DOI: 10.1002/1097-0142(20011101)92:9<2364::aid-cncr1584>3.0.co;2-p] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
101 Sun X, Xu Y, Wang Y, Chen Q, Liu L, Bao Y. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Med Sci Monit 2018;24:3193-203. [PMID: 29763936 DOI: 10.12659/MSM.909977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
102 Karrow N, Mccay J, Brown R, Musgrove D, Pettit D, Munson A, Germolec D, White K. Thalidomide Stimulates Splenic IgM Antibody Response and Cytotoxic T Lymphocyte Activity and Alters Leukocyte Subpopulation Numbers in Female B6C3F1 Mice. Toxicology and Applied Pharmacology 2000;165:237-44. [DOI: 10.1006/taap.2000.8939] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
103 Kuruvilla J, Song K, Mollee P, Panzarella T, Mccrae J, Nagy T, Crump M, Keating A. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology 2013;11:25-9. [DOI: 10.1080/10245330500276592] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
104 Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim Biophys Sin (Shanghai) 2014;46:240-53. [PMID: 24374776 DOI: 10.1093/abbs/gmt142] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
105 Estrada-G I, Garibay-Escobar A, Núñez-Vázquez A, Hojyo-Tomoka T, Vega-Memije E, Cortés-Franco R, Pérez-Uribe A, Flores-Romo L, Santos-Argumedo L, Estrada-Parra S, Domínguez-Soto L. Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo. Int J Dermatol 2004;43:893-7. [PMID: 15569010 DOI: 10.1111/j.1365-4632.2004.02274.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
106 Tadesse A, Abebe M, Bizuneh E, Mulugeta W, Aseffa A, Shannon EJ. Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction. Immunopharmacol Immunotoxicol 2006;28:431-41. [PMID: 16997792 DOI: 10.1080/08923970600928023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
107 Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, Hsieh RK. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10(5): 649-653 [PMID: 14991931 DOI: 10.3748/wjg.v10.i5.649] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
108 Young PR. Pharmacological Modulation of Cytokine Action and Production through Signaling Pathways. Cytokine & Growth Factor Reviews 1998;9:239-57. [DOI: 10.1016/s1359-6101(98)00011-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
109 Kaplan G, Thomas S, Fierer DS, Mulligan K, Haslett PA, Fessel WJ, Smith LG, Kook KA, Stirling D, Schambelan M. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000;16:1345-55. [PMID: 11018854 DOI: 10.1089/08892220050140892] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 2.9] [Reference Citation Analysis]
110 Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033-45. [PMID: 19009291 DOI: 10.1007/s00262-008-0620-4] [Cited by in Crossref: 271] [Cited by in F6Publishing: 253] [Article Influence: 19.4] [Reference Citation Analysis]
111 Steins MB, Padró T, Bieker R, Ruiz S, Kropff M, Kienast J, Kessler T, Buechner T, Berdel WE, Mesters RM. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002;99:834-9. [DOI: 10.1182/blood.v99.3.834] [Cited by in Crossref: 65] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
112 Fink EC, McConkey M, Adams DN, Haldar SD, Kennedy JA, Guirguis AA, Udeshi ND, Mani DR, Chen M, Liddicoat B, Svinkina T, Nguyen AT, Carr SA, Ebert BL. Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 2018;132:1535-44. [PMID: 30064974 DOI: 10.1182/blood-2018-05-852798] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
113 Zeldis JB, Schafer PH, Bennett BL, Mercurio F, Stirling DI. Potential new therapeutics for Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:275-81. [PMID: 12720152 DOI: 10.1053/sonc.2003.50078] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
114 Suppiah R, Srkalovic JG, Hussein MA. Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma. Clin Lymphoma Myeloma 2006;6:301-5. [PMID: 16507207 DOI: 10.3816/CLM.2006.n.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
115 Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301-305. [PMID: 24292625 DOI: 10.1126/science.1244851] [Cited by in Crossref: 854] [Cited by in F6Publishing: 795] [Article Influence: 94.9] [Reference Citation Analysis]
116 Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 2010;116:424-31. [PMID: 19918923 DOI: 10.1002/cncr.24739] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
117 Hussain K, Patel P, Roberts N. The role of thalidomide in dermatology. Clin Exp Dermatol 2021. [PMID: 34779533 DOI: 10.1111/ced.15019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Combe B. Thalidomide: new indications? Joint Bone Spine 2001;68:582-7. [DOI: 10.1016/s1297-319x(01)00326-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
119 Berg SL, Cairo MS, Russell H, Ayello J, Ingle AM, Lau H, Chen N, Adamson PC, Blaney SM. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol 2011;29:316-23. [PMID: 21149673 DOI: 10.1200/JCO.2010.30.8387] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
120 Pönisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U, Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, Haas A, Kreibich U, Niederwieser D; for the East German Study Group of Haematology and Oncology (OSHO). Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. British Journal of Haematology 2008;143:191-200. [DOI: 10.1111/j.1365-2141.2008.07076.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
121 Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma. 2008;49:1238-1245. [PMID: 18452080 DOI: 10.1080/10428190802005191] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 5.4] [Reference Citation Analysis]
122 Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'brien SM, Garcia-manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006;106:1974-84. [DOI: 10.1002/cncr.21827] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
123 Hanan EJ, Liang J, Wang X, Blake RA, Blaquiere N, Staben ST. Monomeric Targeted Protein Degraders. J Med Chem 2020;63:11330-61. [DOI: 10.1021/acs.jmedchem.0c00093] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
124 Dmoszyńska A, Bojarska-Junak A, Domański D, Roliński J, Hus M, Soroka-Wojtaszko M. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2002;43:401-6. [PMID: 11999576 DOI: 10.1080/10428190290006224] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
125 Mesa RA, Steensma DP, Pardanani A, Li C, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-41. [DOI: 10.1182/blood-2002-09-2928] [Cited by in Crossref: 206] [Cited by in F6Publishing: 175] [Article Influence: 10.8] [Reference Citation Analysis]
126 Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005;7:E14-9. [PMID: 16146335 DOI: 10.1208/aapsj070103] [Cited by in Crossref: 125] [Cited by in F6Publishing: 114] [Article Influence: 7.4] [Reference Citation Analysis]
127 Singhal S, Mehta J. Thalidomide in Cancer: Potential Uses and Limitations. BioDrugs 2001;15:163-72. [DOI: 10.2165/00063030-200115030-00003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 2.4] [Reference Citation Analysis]
128 Zeidner JF, Knaus HA, Zeidan AM, Blackford AL, Montiel-Esparza R, Hackl H, Prince GT, Gondek LP, Ghiaur G, Showel MM, DeZern AE, Pratz KW, Douglas Smith B, Levis MJ, Gore S, Coombs CC, Foster MC, Streicher H, Karp JE, Luznik L, Gojo I. Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. Leukemia 2020;34:1563-76. [PMID: 31900407 DOI: 10.1038/s41375-019-0693-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
129 Majumdar S, Lamothe B, Aggarwal BB. Thalidomide Suppresses NF-κB Activation Induced by TNF and H 2 O 2 , But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester. J Immunol 2002;168:2644-51. [DOI: 10.4049/jimmunol.168.6.2644] [Cited by in Crossref: 126] [Cited by in F6Publishing: 108] [Article Influence: 6.3] [Reference Citation Analysis]
130 Zhu X, Giordano T, Yu QS, Holloway HW, Perry TA, Lahiri DK, Brossi A, Greig NH. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J Med Chem. 2003;46:5222-5229. [PMID: 14613324 DOI: 10.1021/jm030152f] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 3.2] [Reference Citation Analysis]
131 Yang Y, Gao S, Fan H, Lin H, Li W, Wang J. Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion. Exp Ther Med 2013;6:803-7. [PMID: 24137269 DOI: 10.3892/etm.2013.1218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
132 Crane E, List A. Immunomodulatory drugs. Cancer Invest 2005;23:625-34. [PMID: 16305990 DOI: 10.1080/07357900500283101] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
133 Oriol A. Pomalidomide in the treatment of multiple myeloma and perspectives in other hematological malignancies. International Journal of Hematologic Oncology 2014;3:223-31. [DOI: 10.2217/ijh.14.16] [Reference Citation Analysis]
134 Mathew S, Bauer KL, Fischoeder A, Bhardwaj N, Oliver SJ. The anergic state in sarcoidosis is associated with diminished dendritic cell function. J Immunol 2008;181:746-55. [PMID: 18566441 DOI: 10.4049/jimmunol.181.1.746] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 4.5] [Reference Citation Analysis]
135 Staitieh BS, Renzoni EA, Veeraraghavan S. Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med 2015;47:100-5. [PMID: 25613169 DOI: 10.3109/07853890.2014.991751] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
136 Schey S, Ramasamy K. Pomalidomide therapy for myeloma. Expert Opin Investig Drugs 2011;20:691-700. [PMID: 21413906 DOI: 10.1517/13543784.2011.567265] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
137 Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427-2437. [PMID: 18551193 DOI: 10.1172/jci35017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 219] [Article Influence: 3.4] [Reference Citation Analysis]
138 Gullestad L, Semb AG, Holt E, Skårdal R, Ueland T, Yndestad A, Frøland SS, Aukrust P. Effect of thalidomide in patients with chronic heart failure. American Heart Journal 2002;144:847-50. [DOI: 10.1067/mhj.2002.125628] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
139 Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol. 2003;21:4444-4454. [PMID: 14645435 DOI: 10.1200/jco.2003.07.200] [Cited by in Crossref: 91] [Cited by in F6Publishing: 16] [Article Influence: 5.1] [Reference Citation Analysis]
140 Noman ASM, Koide N, Hassan F, I.-e-khuda I, Dagvadorj J, Tumurkhuu G, Islam S, Naiki Y, Yoshida T, Yokochi T. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-α production via down-regulation of MyD88 expression. Innate Immun 2009;15:33-41. [DOI: 10.1177/1753425908099317] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
141 Loh HK, Sahoo KC, Kishore K, Ray R, Nag TC, Kumari S, Arya DS. Effects of Thalidomide on Isoprenaline-Induced Acute Myocardial Injury: A Haemodynamic, Histopathological and Ultrastructural Study. Basic Clin Pharmacol Toxicol 2007;100:233-9. [DOI: 10.1111/j.1742-7843.2007.00022.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
142 Rajkumar S, Witzig T. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treatment Reviews 2000;26:351-62. [DOI: 10.1053/ctrv.2000.0188] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 4.0] [Reference Citation Analysis]
143 Prehn JL, Landers C, Muller GW, Man HW, Stirling DI, Targan SR. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J Clin Immunol 2001;21:357-64. [PMID: 11720008 DOI: 10.1023/a:1012292703871] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Gribben JG, Fowler N, Morschhauser F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol 2015;33:2803-11. [PMID: 26195701 DOI: 10.1200/JCO.2014.59.5363] [Cited by in Crossref: 144] [Cited by in F6Publishing: 70] [Article Influence: 20.6] [Reference Citation Analysis]
145 Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis. 1999;58 Suppl 1:I107-I113. [PMID: 10577986 DOI: 10.1136/ard.58.2008.i107] [Cited by in Crossref: 118] [Cited by in F6Publishing: 104] [Article Influence: 5.4] [Reference Citation Analysis]
146 Tsai S, Sabel MS. Translational research in melanoma. Surg Oncol Clin N Am 2008;17:391-419, ix-x. [PMID: 18375359 DOI: 10.1016/j.soc.2007.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
147 Oliver SJ, Moreira A, Kaplan G. Immune Stimulation in Scleroderma Patients Treated with Thalidomide. Clinical Immunology 2000;97:109-20. [DOI: 10.1006/clim.2000.4920] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
148 Baidas S, Tfayli A, Bhargava P. Thalidomide: An Old Drug with New Clinical Applications. Cancer Investigation 2002;20:835-48. [DOI: 10.1081/cnv-120002498] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
149 Jung S, Bae S, Ahn J, Kang S, Yang D, Kim Y, Kim H, Lee J. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. Int J Hematol 2013;97:382-7. [DOI: 10.1007/s12185-013-1270-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
150 Diamanti A, Capriati T, Papadatou B, Knafelz D, Bracci F, Corsetti T, Elia D, Torre G. The clinical implications of thalidomide in inflammatory bowel diseases. Expert Rev Clin Immunol. 2015;11:699-708. [PMID: 25865355 DOI: 10.1586/1744666x.2015.1027687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
151 Schey S. Myeloma. European Journal of Cancer Supplements 2003;1:35-41. [DOI: 10.1016/s1359-6349(03)00006-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
152 Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res. 2012;36 Suppl 1:S3-12. [PMID: 23176722 DOI: 10.1016/s0145-2126(12)70003-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
153 Hussein MA. New treatment strategies for multiple myeloma. Seminars in Hematology 2004;41:2-8. [DOI: 10.1053/j.seminhematol.2004.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
154 Thiele A, Bang R, Gütschow M, Rossol M, Loos S, Eger K, Tiegs G, Hauschildt S. Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide. European Journal of Pharmacology 2002;453:325-34. [DOI: 10.1016/s0014-2999(02)02423-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
155 Man HW, Corral LG, Stirling DI, Muller GW. Alpha-fluoro-substituted thalidomide analogues. Bioorg Med Chem Lett 2003;13:3415-7. [PMID: 14505639 DOI: 10.1016/s0960-894x(03)00778-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
156 Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007;138:563-79. [PMID: 17686051 DOI: 10.1111/j.1365-2141.2007.06705.x] [Cited by in Crossref: 206] [Cited by in F6Publishing: 195] [Article Influence: 13.7] [Reference Citation Analysis]
157 Domingo S, Solé C, Moliné T, Ferrer B, Cortés-hernández J. Thalidomide Exerts Anti-Inflammatory Effects in Cutaneous Lupus by Inhibiting the IRF4/NF-ҡB and AMPK1/mTOR Pathways. Biomedicines 2021;9:1857. [DOI: 10.3390/biomedicines9121857] [Reference Citation Analysis]
158 Hwu W, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN. Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial. JCO 2002;20:2610-5. [DOI: 10.1200/jco.2002.09.034] [Cited by in Crossref: 53] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
159 Tabata C, Tabata R, Kadokawa Y, Hisamori S, Takahashi M, Mishima M, Nakano T, Kubo H. Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice. J Immunol 2007;179:708-14. [DOI: 10.4049/jimmunol.179.1.708] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 4.5] [Reference Citation Analysis]
160 Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer. 2005;103:2590-2597. [PMID: 15861414 DOI: 10.1002/cncr.21081] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 4.7] [Reference Citation Analysis]
161 Schoeman JF, Fieggen G, Seller N, Mendelson M, Hartzenberg B. Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol. 2006;21:301-308. [PMID: 16900926 DOI: 10.1177/08830738060210040801] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
162 Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22-32. [PMID: 19907437 DOI: 10.1038/leu.2009.236] [Cited by in Crossref: 347] [Cited by in F6Publishing: 331] [Article Influence: 26.7] [Reference Citation Analysis]
163 Thomas D, Kantarjian H. The revitalization of thalidomide. Annals of Oncology 2001;12:885-6. [DOI: 10.1023/a:1011123209816] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
164 Lacy MQ, Rajkumar SV. Pomalidomide: A new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. Am J Hematol 2010;85:95-6. [DOI: 10.1002/ajh.21610] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
165 Ginsburg PM, Dassopoulos T, Ehrenpreis ED. Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature. Annals of Medicine 2009;33:516-25. [DOI: 10.3109/07853890108995961] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
166 García-sanz R. Thalidomide in multiple myeloma. Expert Opinion on Pharmacotherapy 2006;7:195-213. [DOI: 10.1517/14656566.7.2.195] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
167 Anderson KC. Targeted therapy for multiple myeloma. Seminars in Hematology 2001;38:286-94. [DOI: 10.1016/s0037-1963(01)90021-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
168 Watters SA, Mlcochova P, Maldarelli F, Goonetilleke N, Pillay D, Gupta RK. Sequential CCR5-Tropic HIV-1 Reactivation from Distinct Cellular Reservoirs following Perturbation of Elite Control. PLoS One 2016;11:e0158854. [PMID: 27403738 DOI: 10.1371/journal.pone.0158854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Gao S, Wang S, Fan R, Hu J. Recent advances in the molecular mechanism of thalidomide teratogenicity. Biomed Pharmacother 2020;127:110114. [PMID: 32304852 DOI: 10.1016/j.biopha.2020.110114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
170 Mancuso A, Sternberg CN. Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice? Critical Reviews in Oncology/Hematology 2005;55:67-81. [DOI: 10.1016/j.critrevonc.2005.03.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
171 Rehman W, Arfons LM, Lazarus HM. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol 2011;2:291-308. [PMID: 23556097 DOI: 10.1177/2040620711413165] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
172 Invernizzi R, Travaglino E, Amici MD, Brugnatelli S, Ramajoli I, Rovati B, Benatti C, Ascari E. Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. Leukemia Research 2005;29:641-7. [DOI: 10.1016/j.leukres.2004.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
173 Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol 2012;67:760-8. [PMID: 22285672 DOI: 10.1016/j.jaad.2011.12.021] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
174 Du GJ, Lin HH, Xu QT, Wang MW. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol 2005;43:112-9. [PMID: 15982930 DOI: 10.1016/j.vph.2005.04.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
175 Lacy MQ. New Immunomodulatory Drugs in Myeloma. Curr Hematol Malig Rep 2011;6:120-5. [DOI: 10.1007/s11899-011-0077-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
176 Elliott MA, Mesa RA, Li C, Hook CC, Ansell SM, Levitt RM, Geyer SM, Tefferi A. Thalidomide treatment in myelofibrosis with myeloid metaplasia: Thalidomide in Myelofibrosis with Myeloid Metaplasia. British Journal of Haematology 2002;117:288-96. [DOI: 10.1046/j.1365-2141.2002.03443.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 4.5] [Reference Citation Analysis]
177 Lafaras C, Mandala E, Verrou E, Platogiannis D, Barbetakis N, Bischiniotis T, Zervas K. Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. Ann Oncol. 2008;19:1765-1769. [PMID: 18480066 DOI: 10.1093/annonc/mdn287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
178 Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG. Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity. J Immunol 2002;168:4914-9. [DOI: 10.4049/jimmunol.168.10.4914] [Cited by in Crossref: 121] [Cited by in F6Publishing: 111] [Article Influence: 6.1] [Reference Citation Analysis]
179 Abood GJ, Nickoloff BJ, Gamelli RL. Treatment Strategies in Toxic Epidermal Necrolysis Syndrome: Where Are We At?: . Journal of Burn Care & Research 2008;29:269-76. [DOI: 10.1097/bcr.0b013e31815f3658] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
180 Hsu C, Chen CN, Chen LT, Wu CY, Hsieh FJ, Cheng AL. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. Radiology. 2005;235:509-516. [PMID: 15858091 DOI: 10.1148/radiol.2352040271] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
181 Mitsiades CS, Chen-Kiang S. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Crit Rev Oncol Hematol 2013;88 Suppl 1:S5-13. [PMID: 23806982 DOI: 10.1016/j.critrevonc.2013.05.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
182 Payvandi F, Wu L, Haley M, Schafer PH, Zhang L, Chen RS, Muller GW, Stirling DI. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cellular Immunology 2004;230:81-8. [DOI: 10.1016/j.cellimm.2004.09.003] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
183 LeBlanc R, Claveau JS, Ahmad I, Delisle JS, Bambace N, Bernard L, Cohen S, Kiss T, Lachance S, Landais S, Roy DC, Sauvageau G, Roy J. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. Clin Transplant 2020;34:e14099. [PMID: 32981146 DOI: 10.1111/ctr.14099] [Reference Citation Analysis]
184 Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363:1802-1811. [PMID: 15172781 DOI: 10.1016/s0140-6736(04)16308-3] [Cited by in Crossref: 364] [Cited by in F6Publishing: 105] [Article Influence: 20.2] [Reference Citation Analysis]
185 Zu Y, Zhang Y, Zhou J, Zhao H, Gui R, Li Z, Li M, Wei X, Song Y. [Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2016;37:334-6. [PMID: 27093999 DOI: 10.3760/cma.j.issn.0253-2727.2016.04.017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
186 Boichenko I, Bär K, Deiss S, Heim C, Albrecht R, Lupas AN, Hernandez Alvarez B, Hartmann MD. Chemical Ligand Space of Cereblon. ACS Omega 2018;3:11163-71. [PMID: 31459225 DOI: 10.1021/acsomega.8b00959] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
187 Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011;117:1605-13. [DOI: 10.1182/blood-2010-04-278432] [Cited by in Crossref: 112] [Cited by in F6Publishing: 113] [Article Influence: 10.2] [Reference Citation Analysis]
188 Xue HX, Fu WY, Cui HD, Yang LL, Zhang N, Zhao LJ. High-dose thalidomide increases the risk of peripheral neuropathy in the treatment of ankylosing spondylitis. Neural Regen Res 2015;10:814-8. [PMID: 26109960 DOI: 10.4103/1673-5374.156988] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
189 Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood 2015;126:2366-9. [PMID: 26438514 DOI: 10.1182/blood-2015-07-567958] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 11.4] [Reference Citation Analysis]
190 Schoeman JF, Springer P, van Rensburg AJ, Swanevelder S, Hanekom WA, Haslett PAJ, Kaplan G. Adjunctive Thalidomide Therapy for Childhood Tuberculous Meningitis: Results of a Randomized Study. J Child Neurol 2004;19:250-7. [DOI: 10.1177/088307380401900402] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 14.8] [Reference Citation Analysis]
191 Mohammadi Kian M, Mohammadi S, Tavallaei M, Chahardouli B, Rostami S, Zahedpanah M, Ghavamzadeh A, Nikbakht M. Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells. Asian Pac J Cancer Prev 2018;19:1127-34. [PMID: 29699374 DOI: 10.22034/APJCP.2018.19.4.1127] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
192 Rafiee P, Stein DJ, Nelson VM, Otterson MF, Shaker R, Binion DG. Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). Am J Physiol Gastrointest Liver Physiol. 2010;298:G167-G176. [PMID: 19926820 DOI: 10.1152/ajpgi.00385.2009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
193 Miyazato K, Tahara H, Hayakawa Y. Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells. Cancer Sci 2020;111:2770-8. [PMID: 32573072 DOI: 10.1111/cas.14538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
194 Lee C, Kim K, Lee H, Nahm FS, Lim Y, Park J, Kim C. The effect of thalidomide on spinal cord ischemia/reperfusion injury in a rabbit model. Spinal Cord 2007;45:149-57. [DOI: 10.1038/sj.sc.3101931] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
195 Fouquet G, Bories C, Guidez S, Renaud L, Herbaux C, Javed S, Facon T, Leleu X. Pomalidomide for multiple myeloma. Expert Review of Hematology 2014;7:719-31. [DOI: 10.1586/17474086.2014.966074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
196 Shannon EJ, Sandoval F. Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide+Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis. Int Immunopharmacol 2010;10:487-92. [PMID: 20123041 DOI: 10.1016/j.intimp.2010.01.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
197 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
198 Karim MY, Ruiz-irastorza G, Khamashta MA, Hughes GR. Update on therapy — thalidomide in the treatment of lupus. Lupus 2001;10:188-92. [DOI: 10.1191/096120301677213822] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
199 Bang SM, Kim SS, Park SH, Ahn JY, Cho EK, Shin DB, Lee JH. Acute exacerbation of chronic hepatitis B during thalidomide therapy for multiple myeloma: a case report. Korean J Intern Med 2004;19:196-8. [PMID: 15481613 DOI: 10.3904/kjim.2004.19.3.196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
200 Santos ES, Goodman M, Byrnes JJ, Fernandez HF. Thalidomide Effects in the Post-transplantation Setting in Patients with Multiple Myeloma. Hematology 2013;9:35-9. [DOI: 10.1080/10245330310001652428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
201 Lacy MQ, Tefferi A. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leuk Lymphoma 2011;52:560-6. [PMID: 21338284 DOI: 10.3109/10428194.2011.552139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
202 Vincent Rajkumar S, Kyle RA. Thalidomide in the Treatment of Plasma Cell Malignancies. JCO 2001;19:3593-5. [DOI: 10.1200/jco.2001.19.16.3593] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
203 Klausner JD, Kaplan G, Haslett PA. Thalidomide in toxic epidermal necrolysis. The Lancet 1999;353:324. [DOI: 10.1016/s0140-6736(05)74905-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
204 Erdem F, Gundogdu M, Kiki I, Capoĝlu I. Autoimmune thyroiditis during thalidomide treatment. Am J Hematol 2006;81:152. [PMID: 16432860 DOI: 10.1002/ajh.20480] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
205 Zweegman S, Huijgens P. Treatment of myeloma: recent developments: . Anti-Cancer Drugs 2002;13:339-51. [DOI: 10.1097/00001813-200204000-00002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
206 Dasanu CA. Immune alterations in untreated and treated multiple myeloma. J Oncol Pharm Pract 2012;18:257-63. [PMID: 21859744 DOI: 10.1177/1078155211412842] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
207 Sibon D, Cannas G, Baracco F, Prebet T, Vey N, Banos A, Besson C, Corm S, Blanc M, Slama B, Perrier H, Fenaux P, Wattel E; on behalf of the Groupe Francophone des Myélodysplasies. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents: Lenalidomide in non-del(5q) Myelodysplastic Syndromes. British Journal of Haematology 2012;156:619-25. [DOI: 10.1111/j.1365-2141.2011.08979.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
208 Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leukemia Research 2004;28:325-32. [DOI: 10.1016/j.leukres.2003.08.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
209 Kuzu B, Ayaz F, Algul O. Synthesis of New Alicyclic Oxalamide Derivatives and Their Differential Immunomodulatory Activities on the Mammalian Cells. J Heterocyclic Chem 2019;56:1946-52. [DOI: 10.1002/jhet.3573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
210 Kröger N, Stübig T, Atanackovic D. Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014;20:168-72. [PMID: 24067503 DOI: 10.1016/j.bbmt.2013.09.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
211 Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011;163:141-72. [PMID: 21265830 DOI: 10.1111/j.1476-5381.2011.01247.x] [Cited by in Crossref: 133] [Cited by in F6Publishing: 131] [Article Influence: 12.1] [Reference Citation Analysis]
212 Aukrust P, Yndestad A, Dam??s JK, Gullestad L. Therapeutic Potential of Anticytokine Therapy in Congestive Heart Failure: . American Journal of Cardiovascular Drugs 2004;4:169-77. [DOI: 10.2165/00129784-200404030-00004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
213 Dauguet N, Fournié J, Poupot R, Poupot M. Lenalidomide down regulates the production of interferon-γ and the expression of inhibitory cytotoxic receptors of human Natural Killer cells. Cellular Immunology 2010;264:163-70. [DOI: 10.1016/j.cellimm.2010.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
214 Ishii K, Barrett AJ. Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol 2016;7:17-39. [PMID: 26834952 DOI: 10.1177/2040620715616544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
215 Raje N, Hideshima T, Anderson KC. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Expert Review of Anticancer Therapy 2014;6:1239-47. [DOI: 10.1586/14737140.6.9.1239] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
216 Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010;24:1934-9. [PMID: 20827286 DOI: 10.1038/leu.2010.190] [Cited by in Crossref: 147] [Cited by in F6Publishing: 130] [Article Influence: 12.3] [Reference Citation Analysis]
217 Shortt J, Hsu A, Martin B, Doggett K, Matthews G, Doyle M, Ellul J, Jockel T, Andrews D, Hogg S, Reitsma A, Faulkner D, Bergsagel P, Chesi M, Heath J, Denny W, Thompson P, Neeson P, Ritchie D, Mcarthur G, Johnstone R. The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound. Cell Reports 2014;7:1009-19. [DOI: 10.1016/j.celrep.2014.04.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
218 Knight R. IMiDs: A Novel Class of Immunomodulators. Seminars in Oncology 2005;32:24-30. [DOI: 10.1053/j.seminoncol.2005.06.018] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 4.3] [Reference Citation Analysis]
219 Anscher MS, Garst J, Marks LB, Larrier N, Dunphy F, Herndon JE 2nd, Clough R, Marino C, Vujaskovic Z, Zhou S, Dewhirst MW, Shafman TD, Crawford J. Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2006;66:477-82. [PMID: 16904841 DOI: 10.1016/j.ijrobp.2006.05.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
220 Dhodapkar MV, Dhodapkar KM. Immune Modulation in Hematologic Malignancies. Semin Oncol 2015;42:617-25. [PMID: 26320065 DOI: 10.1053/j.seminoncol.2015.05.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
221 Antoszczak M, Markowska A, Markowska J, Huczyński A. Old wine in new bottles: Drug repurposing in oncology. European Journal of Pharmacology 2020;866:172784. [DOI: 10.1016/j.ejphar.2019.172784] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
222 Wang J, Chen J, Qiu D, Zeng Z. Regulatory role of DEPTOR‑mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma. Int J Mol Med 2021;47:643-58. [PMID: 33416146 DOI: 10.3892/ijmm.2020.4831] [Reference Citation Analysis]
223 Rajkumar SV, Mesa RA, Tefferi A. A Review of Angiogenesis and Anti-Angiogenic Therapy in Hematologic Malignancies. Journal of Hematotherapy & Stem Cell Research 2002;11:33-47. [DOI: 10.1089/152581602753448522] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
224 Kasamatsu T, Saitoh T, Ino R, Gotoh N, Mitsui T, Shimizu H, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Murakami H. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib. Hematol Oncol 2017;35:711-8. [PMID: 27405747 DOI: 10.1002/hon.2322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
225 Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2008;61:661-8. [PMID: 17589846 DOI: 10.1007/s00280-007-0521-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
226 Waldowska M, Bojarska-Junak A, Roliński J. A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies. Cent Eur J Immunol 2017;42:181-95. [PMID: 28860937 DOI: 10.5114/ceji.2017.69361] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
227 Puzik A, Thiel A, Faust K, Härtel C. Thalidomide has anti-inflammatory properties in neonatal immune cells. Innate Immun 2013;19:42-52. [PMID: 22710762 DOI: 10.1177/1753425912449881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
228 Coll-Martínez B, Delgado A, Crosas B. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents. Molecules 2020;25:E5956. [PMID: 33339292 DOI: 10.3390/molecules25245956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
229 Ruchelman AL, Man HW, Zhang W, Chen R, Capone L, Kang J, Parton A, Corral L, Schafer PH, Babusis D, Moghaddam MF, Tang Y, Shirley MA, Muller GW. Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity. Bioorg Med Chem Lett 2013;23:360-5. [PMID: 23168019 DOI: 10.1016/j.bmcl.2012.10.071] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
230 Laguna C, Martín B, Torrijos A, García-melgares ML, Febrer I. Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica: experiencia clínica y revisión de la literatura especializada. Actas Dermo-Sifiliográficas 2006;97:177-85. [DOI: 10.1016/s0001-7310(06)73376-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
231 Lindner S, Krönke J. The molecular mechanism of thalidomide analogs in hematologic malignancies. J Mol Med 2016;94:1327-34. [DOI: 10.1007/s00109-016-1450-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
232 Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai Y, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50. [DOI: 10.1182/blood.v96.9.2943.h8002943_2943_2950] [Cited by in Crossref: 13] [Article Influence: 0.6] [Reference Citation Analysis]
233 Kortüm KM, Zhu YX, Shi CX, Jedlowski P, Stewart AK. Cereblon binding molecules in multiple myeloma. Blood Rev 2015;29:329-34. [PMID: 25843596 DOI: 10.1016/j.blre.2015.03.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
234 Zhu J, Deng GM, Diab A, Zwingenberger K, Bakhiet M, Link H. Thalidomide prolongs experimental autoimmune neuritis in Lewis rats. Scand J Immunol 1998;48:397-402. [PMID: 9790310 DOI: 10.1046/j.1365-3083.1998.00421.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
235 Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs. 2000;60:273-292. [PMID: 10983733 DOI: 10.2165/00003495-200060020-00003] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 3.6] [Reference Citation Analysis]
236 Molostvov G, Morris A, Rose P, Basu S, Muller G. The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures: Selective Cytokine Inhibitory Drugs in Multiple Myeloma. British Journal of Haematology 2004;124:366-75. [DOI: 10.1046/j.1365-2141.2003.04777.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
237 Lacy MQ, McCurdy AR. Pomalidomide. Blood 2013;122:2305-9. [PMID: 23974193 DOI: 10.1182/blood-2013-05-484782] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
238 Aukrust P, Gullestad L, Ueland T, Damås JK, Yndestad A. Inflammatory and anti‐inflammatory cytokines in chronic heart failure: Potential therapeutic implications. Annals of Medicine 2009;37:74-85. [DOI: 10.1080/07853890510007232] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 8.3] [Reference Citation Analysis]
239 Strupp C, Germing U, Aivado M, Kündgen A, Fenk R, Hünerlitürkoglu A, Kobbe G, Haas R, Gattermann N. The ratio between CD4 + and CD8 + cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. Leukemia & Lymphoma 2009;46:999-1006. [DOI: 10.1080/10428190500078300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
240 Caraffa E, Russo G, Vita S, Lichtner M, Massetti AP, Mastroianni CM, Vullo V, Ciardi MR, Ajassa C. Intracranial tuberculous mass lesions treated with thalidomide in an immunocompetent child from a low tuberculosis endemic country: A case report. Medicine (Baltimore) 2018;97:e11186. [PMID: 30024502 DOI: 10.1097/MD.0000000000011186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
241 Bertamini L, Bonello F, Boccadoro M, Bringhen S. New drugs in early development for treating multiple myeloma: all that glitters is not gold. Expert Opin Investig Drugs 2020;29:989-1004. [PMID: 32434394 DOI: 10.1080/13543784.2020.1772753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Germano G, Mantovani A, Allavena P. Targeting of the innate immunity/inflammation as complementary anti-tumor therapies. Annals of Medicine 2011;43:581-93. [DOI: 10.3109/07853890.2011.595732] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
243 Davis AG, Donovan J, Bremer M, Van Toorn R, Schoeman J, Dadabhoy A, Lai RP, Cresswell FV, Boulware DR, Wilkinson RJ, Thuong NTT, Thwaites GE, Bahr NC; Tuberculous Meningitis International Research Consortium. Host Directed Therapies for Tuberculous Meningitis. Wellcome Open Res 2020;5:292. [DOI: 10.12688/wellcomeopenres.16474.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Li Y, Jiang Z, Xiao Y, Li L, Gao Y. Metabolism of thalidomide by human liver microsome cytochrome CYP2C19 is required for its antimyeloma and antiangiogenic activities in vitro. Hematol Oncol 2012;30:13-21. [PMID: 21638302 DOI: 10.1002/hon.992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
245 Evereklioglu C. Ocular Behçet disease: current therapeutic approaches. Curr Opin Ophthalmol. 2011;22:508-516. [PMID: 21897239 DOI: 10.1016/j.survophthal.2005.04.009] [Cited by in Crossref: 264] [Cited by in F6Publishing: 212] [Article Influence: 24.0] [Reference Citation Analysis]
246 Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008;112:3122-5. [PMID: 18669874 DOI: 10.1182/blood-2008-06-164228] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 5.2] [Reference Citation Analysis]
247 Sponaas AM, Waage A, Vandsemb EN, Misund K, Børset M, Sundan A, Slørdahl TS, Standal T. Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango? Front Immunol 2021;12:636375. [PMID: 33679794 DOI: 10.3389/fimmu.2021.636375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17:775-9. [DOI: 10.1038/sj.leu.2402866] [Cited by in Crossref: 177] [Cited by in F6Publishing: 143] [Article Influence: 9.3] [Reference Citation Analysis]
249 Letribot B, Nascimento M, Cerrato G, Darrigrand R, Salgues V, Renko D, Pruvost A, Alami M, Messaoudi S, Apcher S. Biological Investigation of a Water-Soluble Isoginkgetin-Phosphate Analogue, Targeting the Spliceosome with In Vivo Antitumor Activity. J Med Chem 2022. [PMID: 35235336 DOI: 10.1021/acs.jmedchem.1c01654] [Reference Citation Analysis]
250 D'Souza C, Prince HM, Neeson PJ. Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs. Front Immunol 2021;12:632399. [PMID: 33746969 DOI: 10.3389/fimmu.2021.632399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
251 Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma: Review. British Journal of Haematology 2003;120:10-7. [DOI: 10.1046/j.1365-2141.2003.03929.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
252 Godin AM, Araújo DP, Menezes RR, Brito AM, Melo IS, Coura GM, Soares DG, Bastos LF, Amaral FA, Ribeiro LS, Boff D, Santos JR, Santos DA, Teixeira MM, de Fátima Â, Machado RR, Coelho MM. Activities of 2-phthalimidethanol and 2-phthalimidethyl nitrate, phthalimide analogs devoid of the glutarimide moiety, in experimental models of inflammatory pain and edema. Pharmacol Biochem Behav 2014;122:291-8. [PMID: 24780502 DOI: 10.1016/j.pbb.2014.04.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
253 O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000;36:151-69. [PMID: 10741273 DOI: 10.1016/s0959-8049(99)00241-5] [Cited by in Crossref: 127] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
254 Deng L, Ding W, Granstein RD. Thalidomide Inhibits Tumor Necrosis Factor-α Production and Antigen Presentation by Langerhans Cells. Journal of Investigative Dermatology 2003;121:1060-5. [DOI: 10.1046/j.1523-1747.2003.12565.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
255 Delmonte A, Ghielmini M, Sessa C. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas. Oncologist 2009;14:511-25. [PMID: 19411316 DOI: 10.1634/theoncologist.2008-0214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
256 Dredge K, Dalgleish AG, Marriott JB. Thalidomide analogs as emerging anti-cancer drugs: . Anti-Cancer Drugs 2003;14:331-5. [DOI: 10.1097/00001813-200306000-00001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
257 Milazzo L, Biasin M, Gatti N, Piacentini L, Niero F, Poma BZ, Galli M, Moroni M, Clerici M, Riva A. Thalidomide in the Treatment of Chronic Hepatitis C Unresponsive to Alfa-Interferon and Ribavirin. Am J Gastroenterology 2006;101:399-402. [DOI: 10.1111/j.1572-0241.2006.00350.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
258 Holmberg LA, Becker PS, Bensinger W. Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. Acta Haematol 2017;137:123-31. [PMID: 28355602 DOI: 10.1159/000455937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
259 Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 2006;107:497-505. [PMID: 16795067 DOI: 10.1002/cncr.22038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
260 Stefan DC, Andronikou S, Freeman N, Schoeman J. Recovery of Vision After Adjuvant Thalidomide in a Child With Tuberculous Meningitis and Acute Lymphoblastic Leukemia. J Child Neurol 2009;24:166-9. [DOI: 10.1177/0883073808322329] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
261 Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol 2008;27:111-35. [PMID: 18437602 DOI: 10.1080/08830180801911339] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
262 Tozer GM. Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br J Radiol. 2003;76 Spec No 1:S23-S35. [PMID: 15456711 DOI: 10.1259/bjr/30165281] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 2.9] [Reference Citation Analysis]
263 Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192-203. [DOI: 10.1111/j.1365-2141.2004.05286.x] [Cited by in Crossref: 231] [Cited by in F6Publishing: 214] [Article Influence: 13.6] [Reference Citation Analysis]
264 Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90:955-961. [PMID: 14997189 DOI: 10.1038/sj.bjc.6601579] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 6.3] [Reference Citation Analysis]
265 Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A, Roccaro AM, Gasparini G. Thalidomide: a new anticancer drug? Expert Opin Investig Drugs 2003;12:1211-25. [PMID: 12831355 DOI: 10.1517/13543784.12.7.1211] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
266 Piccaluga P, Visani G, Pileri S, Ascani S, Grafone T, Isidori A, Malagola M, Finelli C, Martinelli G, Ricci P, Baccarani M, Tura S. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 2002;16:1609-14. [DOI: 10.1038/sj.leu.2402596] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
267 Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, Gibson J, Ho PJ, Iland H, Fromm P, Woodland N, Nassif N, Hart D, Joshua DE. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J 2013;3:e148. [PMID: 24036947 DOI: 10.1038/bcj.2013.34] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 8.3] [Reference Citation Analysis]
268 Slawinska-brych A, Zdzisinska B, Mizerska-dudka M, Kandefer-szerszen M. Induction of apoptosis in multiple myeloma cells by a statin–thalidomide combination can be enhanced by p38 MAPK inhibition. Leukemia Research 2013;37:586-94. [DOI: 10.1016/j.leukres.2013.01.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
269 Li T, Timmins HC, Lazarus HM, Park SB. Peripheral neuropathy in hematologic malignancies – Past, present and future. Blood Reviews 2020;43:100653. [DOI: 10.1016/j.blre.2020.100653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
270 Shannon E, Aseffa A, Pankey G, Sandoval F, Lutz B. Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood. Immunopharmacology 2000;46:175-9. [DOI: 10.1016/s0162-3109(99)00169-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
271 Kastritis E, Dimopoulos MA. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opinion on Pharmacotherapy 2007;8:497-509. [DOI: 10.1517/14656566.8.4.497] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
272 Schey S. Thalidomide in the Management of Multiple Myeloma. Hematology 2013;7:291-9. [DOI: 10.1080/1024533021000037199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
273 Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322. [PMID: 15057291 DOI: 10.1038/nrc1323] [Cited by in Crossref: 550] [Cited by in F6Publishing: 481] [Article Influence: 30.6] [Reference Citation Analysis]
274 Gonsalves WI, Milani P, Derudas D, Buadi FK. The next generation of novel therapies for the management of relapsed multiple myeloma. Future Oncol 2017;13:63-75. [PMID: 27513456 DOI: 10.2217/fon-2016-0200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
275 Yang R, Han ZC. Angiogenesis in Hematologic Malignancies and Its Clinical Implications. Int J Hematol 2002;75:246-56. [DOI: 10.1007/bf02982037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
276 Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L, Wong CW, Chang WC, Thomas SH, Sanchez JF, Yang L, Brown CE, Pichiorri F, Htut M, Krishnan AY, Forman SJ. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 2018;24:106-19. [PMID: 29061640 DOI: 10.1158/1078-0432.CCR-17-0344] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
277 Harousseau J. Thalidomide in multiple myeloma: past, present and future. Future Oncology 2006;2:577-89. [DOI: 10.2217/14796694.2.5.577] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
278 Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1999;80:716-23. [PMID: 10360649 DOI: 10.1038/sj.bjc.6690415] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
279 Krown SE. Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematology/Oncology Clinics of North America 2003;17:763-83. [DOI: 10.1016/s0889-8588(03)00042-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
280 Xu S, Li X, Liu Y, Xia Y, Chang R, Zhang C. Inflammasome inhibitors: promising therapeutic approaches against cancer. J Hematol Oncol 2019;12:64. [PMID: 31242947 DOI: 10.1186/s13045-019-0755-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
281 Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, Boccadoro M. New drugs for treatment of multiple myeloma. Lancet Oncol. 2004;5:430-442. [PMID: 15231250 DOI: 10.1016/s1470-2045(04)01511-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
282 Saunders G. Overview of drug therapy for multiple myeloma. J Oncol Pharm Pract 2005;11:83-100. [DOI: 10.1191/1078155205jp160oa] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
283 Li Y, Hou J, Wang D, Fu W, Yuan Z, Chen Y, Tao Z. Prognostic factors for the efficacy of thalidomide in the treatment of multiple myeloma: A clinical study of 110 patients in China. Leukemia & Lymphoma 2006;47:2593-600. [DOI: 10.1080/10428190600955753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
284 Parrish C, Scott GB, Cook G. Immune dysfunction in multiple myeloma. International Journal of Hematologic Oncology 2013;2:49-59. [DOI: 10.2217/ijh.12.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
285 Laffitte E, Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opinion on Drug Safety 2005;3:47-56. [DOI: 10.1517/14740338.3.1.47] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
286 Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216. [PMID: 11418482 DOI: 10.1182/blood.v98.1.210] [Cited by in Crossref: 665] [Cited by in F6Publishing: 205] [Article Influence: 31.7] [Reference Citation Analysis]
287 Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54:683-687. [PMID: 22966948 DOI: 10.3109/10428194.2012.728597] [Cited by in Crossref: 139] [Cited by in F6Publishing: 135] [Article Influence: 13.9] [Reference Citation Analysis]
288 Girgis E, Mahoney J, Darling-Reed S, Soliman M. Arsenic trioxide enhances the cytotoxic effect of thalidomide in a KG-1a human acute mylogenous leukemia cell line. Oncol Lett 2010;1:473-9. [PMID: 21442015 DOI: 10.3892/ol_00000083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
289 Bruno B, Gay F, Boccadoro M, Palumbo A. Management of myeloma: an Italian perspective. Clin Lymphoma Myeloma Leuk 2011;11 Suppl 1:S82-6. [PMID: 22035755 DOI: 10.1016/j.clml.2011.03.026] [Reference Citation Analysis]
290 Schutt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, Flasshove M, Hense J, Bojko P, Metz K, Moritz T, Seeber S, Nowrousian MR. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 2005;74:40-6. [DOI: 10.1111/j.1600-0609.2004.00349.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
291 Grosbois B, Duguet C. Thalidomide : le renouveau. La Revue de Médecine Interne 2001;22:5-7. [DOI: 10.1016/s0248-8663(00)00279-4] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
292 Jin X, Lu S, Xing X, Wang L, Mu D, He M, Huang H, Zeng X, Chen Q. Thalidomide: features and potential significance in oral precancerous conditions and oral cancer. J Oral Pathol Med 2013;42:355-62. [DOI: 10.1111/jop.12004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
293 Dreicer R. Lenalidomide: Immunomodulatory, antiangiogenic, and clinical activity in solid tumors. Curr Oncol Rep 2007;9:120-3. [DOI: 10.1007/s11912-007-0008-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
294 Strasser K, Ludwig H. Thalidomide treatment in multiple myeloma. Blood Reviews 2002;16:207-15. [DOI: 10.1016/s0268-960x(02)00031-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
295 Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J, Tanguturi S, Ladd-Acosta C, Stone R, Golub TR, Raza A. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008;5:e35. [PMID: 18271621 DOI: 10.1371/journal.pmed.0050035] [Cited by in Crossref: 121] [Cited by in F6Publishing: 111] [Article Influence: 8.6] [Reference Citation Analysis]
296 Ridoux O, Drancourt M. Lack of In Vitro Antimicrosporidian Activity of Thalidomide. Antimicrob Agents Chemother 1999;43:2305-6. [DOI: 10.1128/aac.43.9.2305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
297 Singhal S, Mehta J. Novel therapies in multiple myeloma. Int J Hematol 2003;77:226-31. [PMID: 12731664 DOI: 10.1007/BF02983778] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
298 Vergara TRC, Samer S, Santos-Oliveira JR, Giron LB, Arif MS, Silva-Freitas ML, Cherman LA, Treitsman MS, Chebabo A, Sucupira MCA, Da-Cruz AM, Diaz RS; SPARC Working Group. Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety. EBioMedicine 2017;23:59-67. [PMID: 28822719 DOI: 10.1016/j.ebiom.2017.08.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
299 Winqvist M, Mozaffari F, Palma M, Eketorp Sylvan S, Hansson L, Mellstedt H, Österborg A, Lundin J. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. Cancer Immunol Immunother 2017;66:91-102. [PMID: 27815572 DOI: 10.1007/s00262-016-1922-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
300 Sch�tt P, Buttkereit U, Brandhorst D, Lindemann M, Schmiedl S, Grosse-wilde H, Seeber S, Nowrousian MR, Opalka B, Moritz T. In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment. Cancer Immunol Immunother 2005;54:506-12. [DOI: 10.1007/s00262-004-0633-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
301 Hwu W, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma. JCO 2003;21:3351-6. [DOI: 10.1200/jco.2003.02.061] [Cited by in Crossref: 114] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
302 Brinker BT, Waller EK, Leong T, Heffner LT Jr, Redei I, Langston AA, Lonial S. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006;106:2171-80. [PMID: 16598756 DOI: 10.1002/cncr.21852] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
303 Krown SE. Management of Kaposi sarcoma: the role of interferon and thalidomide: . Current Opinion in Oncology 2001;13:374-81. [DOI: 10.1097/00001622-200109000-00010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
304 Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, Abbruzzese JL, Brown TD. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005;103:749-755. [PMID: 15660400 DOI: 10.1002/cncr.20821] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 4.4] [Reference Citation Analysis]
305 Junxun L, Junru L, Meilan C, Chujia L, Shaoqian C, Jieyu Z, Zhuangjian Y, Fan Z, Juan O, Jing C, Juan L. Three Patients with Multiple Myeloma Developing Secondary Lymphoblastic Leukemia: Case Reports and Review of the Literature. Tumori 2016;102:S131-6. [DOI: 10.5301/tj.5000377] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
306 Tabata C, Tabata R, Takahashi Y, Nakamura K, Nakano T. Thalidomide prevents cigarette smoke extract-induced lung damage in mice. International Immunopharmacology 2015;25:511-7. [DOI: 10.1016/j.intimp.2015.02.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
307 Segler A, Tsimberidou AM. Lenalidomide in solid tumors. Cancer Chemother Pharmacol. 2012;69:1393-1406. [PMID: 22584909 DOI: 10.1007/s00280-012-1874-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
308 Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002;130:75-84. [PMID: 12296856 DOI: 10.1046/j.1365-2249.2002.01954.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 98] [Article Influence: 5.8] [Reference Citation Analysis]
309 Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22:3269-76. [PMID: 15249589 DOI: 10.1200/JCO.2004.10.052] [Cited by in Crossref: 241] [Cited by in F6Publishing: 64] [Article Influence: 13.4] [Reference Citation Analysis]
310 Steins MB, Bieker R, Padró T, Kessler T, Kienast J, Berdel WE, Mesters RM. Thalidomide for the Treatment of Acute Myeloid Leukemia. Leukemia & Lymphoma 2010;44:1489-93. [DOI: 10.3109/10428190309178769] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
311 Marriott J, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunology Today 1999;20:538-40. [DOI: 10.1016/s0167-5699(99)01531-5] [Cited by in Crossref: 83] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
312 Morabito A, Carillio G, Longo R, Gasparini G. Thalidomide Is Inactive in Heavily Pretreated Patients with Metastatic Breast Cancer: . The Cancer Journal 2005;11:248-51. [DOI: 10.1097/00130404-200505000-00012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
313 Amini-adle M, Thieulent N, Dalle S, Balme B, Thomas L. Scleromyxedema: Successful Treatment with Thalidomide in Two Patients. Dermatology 2006;214:58-60. [DOI: 10.1159/000096914] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
314 Huang YH, Zhou DB, Han B, Li T, Wang SJ. Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide, vincristine, and prednisone. J Int Med Res 2019;47:1810-4. [PMID: 30806107 DOI: 10.1177/0300060519830242] [Reference Citation Analysis]
315 Mubeen K, Siddiq MA, Jigna VR. Thalidomide: an emerging drug in oral mucosal lesions. Clin J Gastroenterol 2009;2:149-55. [DOI: 10.1007/s12328-009-0089-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
316 Macpherson GR, Franks M, Tomoaia-cotisel A, Ando Y, Price DK, Figg WD. Current status of thalidomide and its role in the treatment of metastatic prostate cancer. Critical Reviews in Oncology/Hematology 2003;46:49-57. [DOI: 10.1016/s1040-8428(03)00064-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
317 Marriott JB, Muller G, Stirling D, Dalgleish AG. Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 2001;1:675-82. [PMID: 11727503 DOI: 10.1517/14712598.1.4.675] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
318 Huang MC, Greig NH, Luo W, Tweedie D, Schwartz JB, Longo DL, Ferrucci L, Ershler WB, Goetzl EJ. Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide. Clin Immunol 2011;138:201-11. [PMID: 21130040 DOI: 10.1016/j.clim.2010.11.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
319 Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res 2012;36:1218-24. [PMID: 22727252 DOI: 10.1016/j.leukres.2012.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
320 Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. Ann Hematol 2005;84:594-600. [DOI: 10.1007/s00277-005-1007-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
321 Borcherding N, Jethava Y, Vikas P. Repurposing Anti-Cancer Drugs for COVID-19 Treatment. Drug Des Devel Ther 2020;14:5045-58. [PMID: 33239864 DOI: 10.2147/DDDT.S282252] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
322 Zhang L, Bi E, Hong S, Qian J, Zheng C, Wang M, Yi Q. CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma. Oncotarget 2015;6:36032-40. [PMID: 26447613 DOI: 10.18632/oncotarget.5506] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
323 Ribatti D, Vacca A. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 2005;19:1525-31. [PMID: 15973447 DOI: 10.1038/sj.leu.2403852] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
324 Silver RT. Myelofibrosis: Thalidomide Finds a New Disease. Mayo Clinic Proceedings 2004;79:857-8. [DOI: 10.4065/79.7.857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
325 Li D, Zhang XW, Jiang XQ, Yin YJ, Fan Z, Sun CB, Chen XH, Li YH, Liu KX. Protective effects of thalidomide on pulmonary injuries in a rat model of paraquat intoxication. J Inflamm (Lond) 2015;12:46. [PMID: 26221080 DOI: 10.1186/s12950-015-0093-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
326 Dong S, Ghobrial IM. Autologous graft versus myeloma: it's not a myth. J Clin Invest 2019;129:48-50. [PMID: 30457981 DOI: 10.1172/JCI125431] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
327 Tsenova L, Mangaliso B, Muller G, Chen Y, Freedman VH, Stirling D, Kaplan G. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob Agents Chemother 2002;46:1887-95. [PMID: 12019105 DOI: 10.1128/AAC.46.6.1887-1895.2002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
328 Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. Hematol Oncol 2008;26:55-65. [DOI: 10.1002/hon.845] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
329 Dimopoulos MA, Eleutherakis-papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. The American Journal of Medicine 2004;117:508-15. [DOI: 10.1016/j.amjmed.2004.03.040] [Cited by in Crossref: 86] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
330 Benson DM Jr. Can NKT cells extinguish smoldering myeloma? Blood 2013;121:418-20. [PMID: 23329692 DOI: 10.1182/blood-2012-11-465849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
331 Ferreira PMP, Costa PMD, Costa ADM, Lima DJB, Drumond RR, Silva JDN, Moreira DRDM, Oliveira Filho GBD, Ferreira JM, Queiroz MGRD, Leite ACL, Pessoa C. Cytotoxic and toxicological effects of phthalimide derivatives on tumor and normal murine cells. An Acad Bras Ciênc 2015;87:313-30. [DOI: 10.1590/0001-3765201520130345] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
332 Oliver SJ. The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide. Curr Rheumatol Rep 2000;2:486-91. [DOI: 10.1007/s11926-000-0025-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
333 Girolamo F, Coppola C, Ribatti D, Trojano M. Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathol Commun 2014;2:84. [PMID: 25047180 DOI: 10.1186/s40478-014-0084-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
334 Sieling PA, Hill PJ, Dobos KM, Brookman K, Kuhlman AM, Fabri M, Krutzik SR, Rea TH, Heaslip DG, Belisle JT, Modlin RL. Conserved mycobacterial lipoglycoproteins activate TLR2 but also require glycosylation for MHC class II-restricted T cell activation. J Immunol 2008;180:5833-42. [PMID: 18424702 DOI: 10.4049/jimmunol.180.9.5833] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
335 Okafor MC. Thalidomide for erythema nodosum leprosum and other applications. Pharmacotherapy 2003;23:481-93. [PMID: 12680478 DOI: 10.1592/phco.23.4.481.32115] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
336 McCurdy AR, Lacy MQ. Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol 2013;4:211-6. [PMID: 23730498 DOI: 10.1177/2040620713480155] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
337 Ryoo JJ, Cole CE, Anderson KC. Novel therapies for multiple myeloma. Blood Rev 2002;16:167-74. [PMID: 12163002 DOI: 10.1016/s0268-960x(02)00009-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
338 Bhaskar S, Benson DM. Current and future immunotherapeutic approaches to multiple myeloma therapy. International Journal of Hematologic Oncology 2015;4:23-31. [DOI: 10.2217/ijh.14.43] [Reference Citation Analysis]
339 Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141:41-51. [PMID: 18324965 DOI: 10.1111/j.1365-2141.2008.07013.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 83] [Article Influence: 7.2] [Reference Citation Analysis]
340 Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. J Cell Mol Med 2002;6:160-74. [PMID: 12169202 DOI: 10.1111/j.1582-4934.2002.tb00184.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
341 Jeyakumar A, Chalas E, Hindenburg A. Sustained Complete Remission in a Patient with Platinum-Resistant Ovarian Yolk Sac Tumor. Gynecologic Oncology 2001;82:578-80. [DOI: 10.1006/gyno.2001.6327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
342 Mannheim D, Versari D, Daghini E, Gössl M, Galili O, Chade A, Rajkumar VS, Ritman EL, Lerman LO, Lerman A. Impaired myocardial perfusion reserve in experimental hypercholesterolemia is independent of myocardial neovascularization. Am J Physiol Heart Circ Physiol 2007;292:H2449-58. [PMID: 17208989 DOI: 10.1152/ajpheart.01215.2006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
343 Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable Responses to Thalidomide-Based Drug Therapy for Myelofibrosis With Myeloid Metaplasia. Mayo Clinic Proceedings 2004;79:883-9. [DOI: 10.4065/79.7.883] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
344 Otáhal P, Průková D, Král V, Fabry M, Vočková P, Latečková L, Trněný M, Klener P. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology 2016;5:e1115940. [PMID: 27141398 DOI: 10.1080/2162402X.2015.1115940] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 5.1] [Reference Citation Analysis]
345 Wechalekar AD, Chen CI, Sutton D, Reece D, Voralia M, Stewart AK. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. Leuk Lymphoma 2003;44:1147-9. [PMID: 12916866 DOI: 10.1080/1042819031000067918] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
346 Luzzio FA, Figg WD. Thalidomide analogues: derivatives of an orphan drug with diverse biological activity. Expert Opinion on Therapeutic Patents 2005;14:215-29. [DOI: 10.1517/13543776.14.2.215] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
347 Jones JR, Pawlyn C, Davies FE, Morgan GJ. The safety of pomalidomide for the treatment of multiple myeloma. Expert Opinion on Drug Safety 2016;15:535-47. [DOI: 10.1517/14740338.2016.1154039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
348 Kontogiannis V, Powell RJ. Use of Thalidomide in Dermatological Indications: . BioDrugs 2000;13:255-65. [DOI: 10.2165/00063030-200013040-00004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
349 Singhal S, Mehta J. Thalidomide in cancer. Biomedicine & Pharmacotherapy 2002;56:4-12. [DOI: 10.1016/s0753-3322(01)00146-9] [Cited by in Crossref: 74] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
350 Offidani M, Corvatta L, Polloni C, Gentili S, Brioni A, Visani G, Galieni P, Brunori M, Alesiani F, Catarini M, Centurioni R, Samori A, Blasi N, Ferranti M, Fraticelli P, Mele A, Rizzi R, Larocca F, Leoni P. Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. Leuk Lymphoma 2011;52:776-85. [PMID: 21338282 DOI: 10.3109/10428194.2011.555027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
351 Kuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma. Hematology/Oncology Clinics of North America 2003;17:1459-66. [DOI: 10.1016/s0889-8588(03)00112-6] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
352 Sleijfer S, Kruit WH, Stoter G. Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 2004;40:2377-82. [PMID: 15519508 DOI: 10.1016/j.ejca.2004.07.023] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
353 Derudas D, Capraro F, Martinelli G, Cerchione C. Old and new generation immunomodulatory drugs in multiple myeloma. Panminerva Med 2020;62:207-19. [PMID: 32955182 DOI: 10.23736/S0031-0808.20.04125-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
354 Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86-93. [PMID: 17893227 DOI: 10.1182/blood-2007-01-068833] [Cited by in Crossref: 316] [Cited by in F6Publishing: 282] [Article Influence: 21.1] [Reference Citation Analysis]
355 Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, Miesowicz F, Dhodapkar KM, Dhodapkar MV. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2013;121:423-30. [PMID: 23100308 DOI: 10.1182/blood-2012-06-435503] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 11.2] [Reference Citation Analysis]
356 Gupta D, Hideshima T, Anderson KC. NOVEL BIOLOGICALLY BASED THERAPEUTIC STRATEGIES IN MYELOMA. Reviews in Clinical and Experimental Hematology 2002;6:301-24. [DOI: 10.1046/j.1468-0734.2002.00082.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
357 Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res 2016;22:2359-67. [PMID: 26733610 DOI: 10.1158/1078-0432.CCR-15-2476] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
358 Leitch HA, Buckstein R, Shamy A, Storring JM. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline. Critical Reviews in Oncology/Hematology 2013;85:162-92. [DOI: 10.1016/j.critrevonc.2012.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
359 Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, Wolbring G, Govinda S, Corral LG, Payvandi F, Muller GW, Stirling DI. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305:1222-32. [PMID: 12649301 DOI: 10.1124/jpet.102.048496] [Cited by in Crossref: 138] [Cited by in F6Publishing: 131] [Article Influence: 7.3] [Reference Citation Analysis]
360 Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai Y, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50. [DOI: 10.1182/blood.v96.9.2943] [Cited by in Crossref: 645] [Article Influence: 29.3] [Reference Citation Analysis]
361 Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G. Thalidomide in the management of multiple myeloma. Semin Hematol 2001;38:250-9. [PMID: 11486313 DOI: 10.1016/s0037-1963(01)90017-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
362 Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist 2005;10:718-27. [PMID: 16249352 DOI: 10.1634/theoncologist.10-9-718] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
363 Melchert M, List A. The thalidomide saga. The International Journal of Biochemistry & Cell Biology 2007;39:1489-99. [DOI: 10.1016/j.biocel.2007.01.022] [Cited by in Crossref: 156] [Cited by in F6Publishing: 146] [Article Influence: 10.4] [Reference Citation Analysis]
364 Durie BG. Role of new treatment approaches in defining treatment goals in multiple myeloma – the ultimate goal is extended survival. Cancer Treatment Reviews 2010;36:S18-23. [DOI: 10.1016/s0305-7372(10)70008-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
365 González Á. The Therapy of Pulmonary Fibrosis in Paracoccidioidomycosis: What Are the New Experimental Approaches? J Fungi (Basel) 2020;6:E217. [PMID: 33050568 DOI: 10.3390/jof6040217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Arora B, Mesa R, Tefferi A. Angiogenesis and Anti-angiogenic Therapy in Myelofibrosis with Myeloid Metaplasia. Leukemia & Lymphoma 2009;45:2373-86. [DOI: 10.1080/10428190400003267] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
367 Li J, Zhan J, Zhang F, Ye Z, Ouyang J. Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report. Oncol Lett 2016;12:847-56. [PMID: 27446359 DOI: 10.3892/ol.2016.4728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
368 Dhodapkar MV, Richter J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol 2011;140:160-6. [PMID: 21233022 DOI: 10.1016/j.clim.2010.12.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
369 Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys 2008;71:79-86. [PMID: 18164847 DOI: 10.1016/j.ijrobp.2007.09.016] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
370 Wang ES, Verano AL, Nowak RP, Yuan JC, Donovan KA, Eleuteri NA, Yue H, Ngo KH, Lizotte PH, Gokhale PC, Gray NS, Fischer ES. Acute pharmacological degradation of Helios destabilizes regulatory T cells. Nat Chem Biol 2021;17:711-7. [PMID: 34035522 DOI: 10.1038/s41589-021-00802-w] [Reference Citation Analysis]
371 Drach J, Seidl S, Kaufmann H. Treatment of mantle cell lymphoma: targeting the microenvironment. Expert Rev Anticancer Ther 2005;5:477-85. [PMID: 16001955 DOI: 10.1586/14737140.5.3.477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
372 Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4. [PMID: 11435324 DOI: 10.1182/blood.v98.2.492] [Cited by in Crossref: 405] [Cited by in F6Publishing: 52] [Article Influence: 19.3] [Reference Citation Analysis]
373 Palencia G, Arrieta O, Ríos C, Altagracia M, Kravzov J, Sotelo J. Effect of thalidomide in different tumors in rodents: Effect of thalidomide in tumors. Journal of Experimental Therapeutics and Oncology 2002;2:158-62. [DOI: 10.1046/j.1359-4117.2002.01011.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
374 Braun J, Breban M, Maksymowych WP. Therapy for ankylosing spondylitis: new treatment modalities. Best Practice & Research Clinical Rheumatology 2002;16:631-51. [DOI: 10.1053/berh.2002.0245] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
375 Kumar S, Raje N, Hideshima T, Ishitsuka K, Podar K, Gouille SL, Chauhan D, Richardson P, Munshi NC, Anderson K. FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol 2006;132:698-704. [DOI: 10.1111/j.1365-2141.2005.05946.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
376 Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma. JCO 2002;20:4319-23. [DOI: 10.1200/jco.2002.02.116] [Cited by in Crossref: 382] [Cited by in F6Publishing: 60] [Article Influence: 19.1] [Reference Citation Analysis]
377 Hattori Y, Iguchi T. Thalidomide for the treatment of multiple myeloma. Congenit Anom (Kyoto) 2004;44:125-36. [PMID: 15327481 DOI: 10.1111/j.1741-4520.2004.00025.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
378 Bouscary D, Legros L, Tulliez M, Dubois S, Mahe B, Beyne-rauzy O, Quarre MC, Vassilief D, Varet B, Aouba A, Gardembas M, Giraudier S, Guerci A, Rousselot P, Gaillard F, Moreau A, Rousselet MC, Ifrah N, Fenaux P, Dreyfus F; For The Groupe Francais des Myelodysplasies (GFM). A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br J Haematol 2005;131:609-18. [DOI: 10.1111/j.1365-2141.2005.05817.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
379 Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. JCO 2009;27:5008-14. [DOI: 10.1200/jco.2009.23.6802] [Cited by in Crossref: 231] [Cited by in F6Publishing: 85] [Article Influence: 17.8] [Reference Citation Analysis]
380 Lutzky J, Weber R, Nunez Y, Gillett M, Spitler L. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. J Immunother 2009;32:79-85. [PMID: 19307996 DOI: 10.1097/CJI.0b013e31818c8aaf] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
381 Strupp C, Germing U, Scherer A, Kündgen A, Mödder U, Gattermann N, Haas R. Thalidomide for the treatment of idiopathic myelofibrosis: Thalidomide for IMF. European Journal of Haematology 2004;72:52-7. [DOI: 10.1046/j.0902-4441.2003.00188.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
382 Feyler S, Selby PJ, Cook G. Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Rev. 2013;27:155-164. [PMID: 23623928 DOI: 10.1016/j.blre.2013.04.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
383 Miceli-richard C, Dougados M. Medical Treatment for Ankylosing Spondylitis. In: van Royen B, Dijkmans B, editors. Ankylosing Spondylitis. CRC Press; 2006. pp. 163-8. [DOI: 10.3109/9780849374463-12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
384 Cattelan AM, Trevenzoli M, Aversa SML. Novel pharmacological therapies for the treatment of AIDS-related Kaposi’s sarcoma. Expert Opinion on Investigational Drugs 2005;13:501-13. [DOI: 10.1517/13543784.13.5.501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
385 Merchionne F, Perosa F, Dammacco F. New therapies in multiple myeloma. Clin Exp Med 2007;7:83-97. [PMID: 17972050 DOI: 10.1007/s10238-007-0134-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
386 Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med. 2000;108:487-495. [PMID: 10781782 DOI: 10.1016/s0002-9343(99)00408-8] [Cited by in Crossref: 226] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
387 Ritchie DS, Quach H, Fielding K, Neeson P. Drug-mediated and cellular immunotherapy in multiple myeloma. Immunotherapy 2010;2:243-55. [PMID: 20635931 DOI: 10.2217/imt.10.9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
388 Panousis K, Nikolaou VS, Tsaganos T, Lallos S, Giamarellos-Bourboulis EJ, Efstathopoulos N. Thalidomide prolongs survival after experimental musculoskeletal injury, through an effect on mononuclear apoptosis. J Surg Res 2014;188:198-205. [PMID: 24361040 DOI: 10.1016/j.jss.2013.11.1104] [Reference Citation Analysis]